Lv11
10 积分 2025-07-31 加入
Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor–T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1)
24天前
已完结
Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial
24天前
已完结
Value in Using CAR T Cells for DLBCL
24天前
已完结
Value in Using CAR T Cells for DLBCL
24天前
已关闭
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
24天前
已完结
Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study
24天前
已完结
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study
24天前
已完结
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study
24天前
已完结
Immunotherapy in patients with early-stage microsatellite instable (MSI-H)/ mismatch repair deficient (dMMR) colorectal cancer (CRC) treated in a community setting
1个月前
已关闭
皖公网安备34019202002308
